In each model, key genes have been eliminated or substituted by their counterparts human improving pharmacokinetic evaluation and safety of the drug candidates through the generation of research results that are most predictive of human beings. Together, Taconic and CXR Biosciences are investigators trained with new and sophisticated tools that may revolutionize drug discovery and provide a strong competitive advantage, said Todd Little, President and Chief Executive of Taconic. Our new transADMET models allow researchers can progress in the discovery of drugs more effectively, to minimize the chances of failure in the last phase and improve time to market with new viable pharmacological therapies. The innovative transADMET models will transform pharmaceutical research and the chemical safety assessment, allowing scientists to reflect more accurately the human situation in studies Preclinical, thus reducing the likelihood that occur later problems in clinical trials, said Tom Shepherd, CEO, CXR Biosciences. The decision of Taconic’s settle here to develop this platform with CXR will establish a unique ability and leader in the world in the field of translational research in Scotland. Rhona Allison, senior director of the life sciences, Scottish Enterprise, said: despite the difficult economic conditions, the Scottish life sciences sector has continued to grow and develop in recent years. Taconic investment in this specialized center is a strong indication of continued confidence in Scotland as an excellent venue for the life sciences.
The transADMET program is the culmination of a five-year effort and $13 million financed by ITI Life Sciences. CXR Biosciences validated models transADMET, while TaconicArtemis acted as the main generator of new models. About Taconic Taconic Farms, Inc. was founded in 1952 as a family business in the Valley of the Hudson River in New York. Since then, the company became one of largest providers of rodents of laboratory in the world, being famous for continuous rats and mice well-defined and high-quality parenting. The expertise of Taconic in the design and special generation of genetically modified mice, mice and rats breeding, barrier, genetics and animal health systems serves as support for researchers who are dedicated to the development of drugs using in vivo models. Taconic has six breeding facilities and three laboratories of service in the United States and Europe, a staff consisting of more than 1,000 employees and a commitment to technological innovation.
Additional information about Taconic is available through its website. About CXR Biosciences founded in 2001, CXR Biosciences has used its collaborative approach, models of ownership and cutting-edge expertise to help its clients, whatever its magnitude, to resolve issues concerning the selection of drug candidates or the safety of compounds. CXR develops platforms of preclinical technologies that are most predictive of response to drugs in humans, and provides preclinical special services in the areas of drug development and research toxicology. The company maintains business relations with more than sixty clients and collaborators, including pharmaceutical companies, chemical companies, biotechnology companies, as well as major universities and research institutions.